ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
Benefits of SGLT2 inhibitors on cardiovascular and renal health in clinical practice
Fatma Ben Abdessalem 1 , Hamza Elfekih 1 , Wiem Saafi 1 , Sawsen Nouira 1 , Sawssen Mrad 2 , Imen Halloul 1 , Taieb Ach 1 , Salima Ferchichi 2 , Ghada Saad 1 & Yosra Hasni 1
1University of Sousse, Faculty of Medicine of Sousse, Farhat Hached University Hospital, Endocrinology Diabetology Department, 4000, Sousse, Tunisia, Sousse, Tunisia; 2University of Sousse, Faculty of Medicine of Sousse, Farhat Hached University Hospital, Biochemistry Department, 4000, Sousse, Tunisia, Sousse, Tunisia
JOINT3369
Background: SGLT2-inhibitors have revolutionized the management of type 2 diabetes mellitus by promoting urinary glucose excretion, thereby reducing blood glucose levels. Beyond their role in diabetes management, these agents have shown promise in mitigating cardiovascular and renal complications. This study aimed to evaluate the effects of SGLT2-inhibitors on glycemic control, renal function, and metabolic parameters in patients with diabetes.
Methods: A descriptive retrospective study was conducted at the Endocrinology Department of Farhat-Hached University Hospital in Sousse, Tunisia. The study included diabetic patients evaluated over two periods: P1 from January to March 2024 and P2 from March to June 2024. They were divided into two groups: those receiving SGLT2-inhibitor treatment in P2 (G1) and a control group (G2). All patients underwent fasting blood glucose (FBG), glycated hemoglobin (A1c), lipid profile, renal assessment, and microalbuminuria testing.
Results: A total of 72 patients were evaluated. G1 included 36 patients, and G2 also consisted of 36 patients. The mean age of participants was 64±9.26 years in G1 and 62±8.64 years in G2, with no significant difference (P = 0.36). Both groups had a female predominance (55.5%). Chronic imbalance of diabetes under insulin was the most common reason for admission (52.8%). During P1, no significant differences were observed in A1c, FBG, creatinine, or microalbuminuria between the groups. However, during P2, G1 demonstrated significantly lower A1c (9.07%±1.82% vs. 10.16%±1.40%, P = 0.007) and FBG levels (1.51±0.57 g/l vs. 2.36±0.80 g/l, P<10-3) compared to G2. Microalbuminuria was also significantly reduced in G1 (65±111.18 mg/24h vs. 492±1137.80 mg/24h, P = 0.032). No significant differences were noted in lipid profiles or creatinine levels between the groups.
Conclusion: SGLT2-inhibitors significantly improved glycemic control and reduced microalbuminuria in diabetic patients, highlighting their potential to slow the progression of chronic kidney disease (CKD). Their efficacy and safety across CKD stages 1 to 4 position them as a promising therapeutic option for managing diabetes and its renal complications.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more